Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.38 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 09/30/15 All times are local (Market data is delayed by at least 15 minutes).

itamar medical ltd (ITMMF) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/19/14 - $0.51
52 Week Low
09/4/15 - $0.34
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ITAMAR MEDICAL LTD (ITMMF)

Related News

No related news articles were found.

itamar medical ltd (ITMMF) Related Businessweek News

No Related Businessweek News Found

itamar medical ltd (ITMMF) Details

Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the diagnosis of cardiological conditions and sleep breathing disorders worldwide. It offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient’s peripheral arterial pulse volumes and various parameters of arterial activities. The company offers WatchPAT device, which diagnoses sleep breathing disorders; and EndoPAT device that diagnoses endothelial Dysfunction. It also develops companion diagnostic products to support drug discovery and development from inception through to regulatory approval and launch. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was founded in 1997 and is based in Caesarea, Israel.

Founded in 1997

itamar medical ltd (ITMMF) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: 1.5M
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: 692.0K
Vice President of Operations - U.S. Subsidiar...
Total Annual Compensation: 473.0K
Vice President of Sales - U.S. Subsidiary
Total Annual Compensation: 415.0K
Vice President of Sales
Total Annual Compensation: 448.0K
Compensation as of Fiscal Year 2014.

itamar medical ltd (ITMMF) Key Developments

Itamar Medical Ltd. Announces Board Changes

Viola Private Equity has announced a private investment in public equity (PIPE) deal, of up to $28.4 million in Itamar Medical Ltd. As part of the investment, Jonathan Kolber, General Partner at Viola Private Equity and former Koor Industries CEO, and Sami Totah, General Partner at Viola Private Equity and Amdocs COO, will join Itamar Medical's Board of Directors.

Itamar Medical Ltd. Offers Total Sleep Apnea Management Solution to Cardiologists

Itamar Medical Ltd. announced that it expanding its business model by offering a comprehensive sleep apnea management solution to cardiologists, who seek to create a streamlined pathway for effective treatment. Itamar Medical markets the WatchPAT home sleep test and now offers a solution to manage the entire OSA care continuum for hospitals and clinics. As part of its Total Sleep Solution offering, Itamar will utilize its nationwide network of independent diagnostic testing facilities, durable medical equipment service providers and sleep physicians. Also utilized will be Itamar's cloud-based IT platform solution, the CloudPAT, which encodes and transmits WatchPAT test results directly to physicians and their staff. The company believes this strategy further emphasizes the competitive advantages of the WatchPAT device.

Itamar Medical Inc. and Arterial Health International Sign Representation Agreement

Itamar Medical Inc. and Arterial Health International LLC (AHI) announced they have signed last month a representation agreement. Under the terms of the agreement, AHI will be Itamar's exclusive cardiovascular diagnostic testing service representative and will market both EndoPAT and WatchPAT to physicians in ten states in the US. AHI will continue to offer EndoPAT testing as a key component of the cardiovascular diagnostic test package it offers to primary care physicians and their patients. In addition, WatchPAT testing will also be added as a part of AHI's suite of services. As part of the three-year agreement, AHI is also committed to an annual minimum purchase requirement of EndoPAT and WatchPAT devices and accessories from Itamar Medical. The EndoPAT, manufactured by Itamar Medical, is a device used to test the functioning of the endothelial layer that regulates arterial function. It is the only FDA-cleared device intended for assessing endothelial function, diagnosing coronary artery disease risk and other cardiovascular diseases.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ITMMF:US $0.38 USD 0.00

ITMMF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ITMMF.
View Industry Companies

Industry Analysis


Industry Average

Valuation ITMMF Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ITAMAR MEDICAL LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at